Last reviewed · How we verify
Venetoclax-Decitabine/Azacitidine Association
Venetoclax targets and inhibits BCL-2, a protein that prevents apoptosis, while Decitabine/Azacitidine work as hypomethylating agents to restore normal gene expression.
Venetoclax targets and inhibits BCL-2, a protein that prevents apoptosis, while Decitabine/Azacitidine work as hypomethylating agents to restore normal gene expression. Used for Acute myeloid leukemia (AML).
At a glance
| Generic name | Venetoclax-Decitabine/Azacitidine Association |
|---|---|
| Sponsor | The First Affiliated Hospital with Nanjing Medical University |
| Drug class | BCL-2 inhibitor/hypomethylating agent |
| Target | BCL-2 |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Venetoclax's mechanism of action involves binding to BCL-2, preventing its anti-apoptotic function, thereby allowing for programmed cell death. Decitabine and Azacitidine, on the other hand, act as hypomethylating agents, which means they reduce DNA methylation, leading to the reactivation of silenced genes and the induction of apoptosis in cancer cells.
Approved indications
- Acute myeloid leukemia (AML)
Common side effects
- Neutropenia
- Thrombocytopenia
- Anemia
Key clinical trials
- Trial of DFP-10917 vs Non-Intensive or Intensive Reinduction for AML Patients in 2nd/3rd/4th Salvage (PHASE3)
- Molecular Genetics Guide the Maintenance Therapy After Allogeneic Hematopoietic Stem Cell Transplantation (PHASE2, PHASE3)
- Venetoclax and Decitabine Assessment in Patients (≥60 - <75 Years) with Newly Diagnosed AML Eligible for Allo-SCT (PHASE2)
- Venetoclax+HMA+Aclarubicin Versus Venetoclax+HMA in Treatment-Naive Elderly Patients With AML (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: